Return to homepagePandemic Pact

to identify potent anti-SARS-CoV-2 mAbs to protect vulnerable populations from COVID-19

Grant number: INV-006133

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2020

  • Known Financial Commitments (USD)

    $2,730,874

  • Funder

    Gates Foundation

  • Principal Investigator

    N/A

  • Research Location

    United States of America

  • Lead Research Institution

    La Jolla Institute for Immunology

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Vulnerable populations unspecified

  • Occupations of Interest

    Unspecified

Abstract

N/A

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants.

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5.

GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2.

Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern.

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2.